Transcat/$TRNS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Transcat
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.
- Ticker
- $TRNS
- Sector
- Industrials
- Primary listing
- NASDAQ
- Employees
- 1,413
- Headquarters
- Rochester, United States
- Website
- www.transcat.com
Transcat Metrics
BasicAdvanced
$838M
248.50
$0.36
0.67
-
Price and volume
Market cap
$838M
Beta
0.67
52-week high
$100.00
52-week low
$50.23
Average daily volume
147K
Financial strength
Current ratio
2.492
Quick ratio
1.931
Long term debt to equity
0.458
Total debt to equity
0.458
Interest coverage (TTM)
2.73%
Profitability
EBITDA (TTM)
42.984
Gross margin (TTM)
32.50%
Net profit margin (TTM)
0.99%
Operating margin (TTM)
4.44%
Effective tax rate (TTM)
38.56%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
2.18%
Return on equity (TTM)
1.16%
Valuation
Price to earnings (TTM)
248.498
Price to revenue (TTM)
2.401
Price to book
2.77
Price to tangible book (TTM)
-398.4
Price to free cash flow (TTM)
32.978
Free cash flow yield (TTM)
3.03%
Free cash flow per share (TTM)
2.715
Growth
Revenue change (TTM)
20.91%
Earnings per share change (TTM)
-74.99%
3-year revenue growth (CAGR)
13.78%
10-year revenue growth (CAGR)
10.74%
3-year earnings per share growth (CAGR)
-36.10%
10-year earnings per share growth (CAGR)
-5.44%
What the Analysts think about Transcat
Analyst ratings (Buy, Hold, Sell) for Transcat stock.
Analyst projections of the future price of Transcat stock.
Bulls say / Bears say
Service growth is accelerating: organic revenue rose 16% in the second quarter, and Transcat raised its full-year service growth outlook to the low double digits. Service gross margin expanded by 220 basis points, supporting the case that growth is translating into better operating leverage. (SEC)
The Southeastern Biomedical acquisition extends Transcat’s accredited calibration and maintenance reach across hospital networks in the south-eastern United States. It adds capabilities in a regulated market where calibration is tied to patient safety and compliance, supporting the company’s strategy to grow its service footprint. (Transcat)
Profit growth outpaced sales in the second quarter: revenue rose 18%, adjusted EBITDA increased 23%, and adjusted EBITDA margin widened to 15.4%. Year-to-date operating free cash flow also grew 46%, giving the company more capacity to invest and pursue acquisitions. (The Motley Fool)
Transcat’s acquisition-led expansion has increased borrowing: debt stood at $116.9 million and leverage was 2.18 times at the end of September. Higher debt raises interest costs and leaves less room for error if growth or integration disappoints. (StreetInsider)
Distribution remains a weak spot: its second-quarter gross margin fell 120 basis points year on year, while adjusted operating income declined 9%. The used-equipment sales supporting rental-fleet reinvestment may weigh on segment profitability even as revenue grows. (SEC)
The shares carry a demanding valuation: MarketBeat reported a price-to-earnings ratio of about 242 after the latest results. That leaves the stock vulnerable if strong growth and margin improvement do not continue to meet expectations. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Transcat Financial Performance
Revenues and expenses
Transcat Earnings Performance
Company profitability
Upcoming events
No upcoming events
Transcat News
AllArticlesVideos
Funds containing Transcat
Fund name | Fund size | $TRNS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.